Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 10/20 | 0.50 |
| ▸ | KDR | P35968 | 10/20 | 0.50 |
| ▸ | JAK3 | P52333 | 10/20 | 0.50 |
| ▸ | TNK2 | Q07912 | 10/20 | 0.50 |
| ▸ | AURKA | O14965 | 8/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3639101 | 0.86 | LCK (0.47) | LCKKDRJAK3TNK2AURKA | |
| SCHEMBL3047782 | 0.84 | LCK (0.43) | LCKKDRJAK3TNK2AURKA | |
| SCHEMBL3059041 | 0.82 | LCK (0.41) | LCKKDRJAK3TNK2AURKA | |
| SCHEMBL3042868 | 0.78 | LCK (0.50) | LCKKDRJAK3TNK2AURKA | |
| SCHEMBL13087630 | 0.77 | LCK (0.45) | LCKKDRJAK3TNK2AURKA | |
| SCHEMBL13097717 | 0.76 | TNK2 (0.47) | LCKKDRJAK3TNK2AURKA | |
| SCHEMBL3051089 | 0.75 | TNK2 (0.45) | LCKKDRJAK3TNK2AURKA | |
| SCHEMBL3053707 | 0.75 | AURKA (0.47) | LCKKDRJAK3TNK2AURKA | |
| SCHEMBL3056028 | 0.73 | CHEK1 (0.44) | LCKKDRJAK3TNK2AURKA | |
| SCHEMBL3053705 | 0.71 | CHEK1 (0.48) | KDRTNK2AURKACHEK1MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261736-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | LAMPE THOMAS | 2010-10-14 | — | — | US | disclosed |
| US-20100261736-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | LAMPE THOMAS | 2010-10-14 | — | — | US | disclosed |
| US-20100261736-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | LAMPE THOMAS | 2010-10-14 | — | — | US | disclosed |
| EP-2167482-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | Bayer Schering Pharma AG (DE) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008155017-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008155017-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261736-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | HMGCR, PCSK9, FABP3 | LCK 3301/4885KDR 1489/4885JAK3 3715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.